MedTrace Logo

University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

NCT02508259 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-07-16

Study results available
· View outcomes & findings →

Summary

This study is designed to test the safety and efficacy of a single, intravenous dose of suramin in autism spectrum disorders (ASD).

Conditions

  • Autism Spectrum Disorders

Interventions

DRUG

Suramin

20 mg/kg IV in 50 ml saline over 30 minutes

DRUG

Saline

50 ml IV over 30 minutes

Sponsors & Collaborators

Principal Investigators

  • Robert K Naviaux, MD, PhD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02508259 on ClinicalTrials.gov